Methner Carmen, Chouchani Edward T, Buonincontri Guido, Pell Victoria R, Sawiak Stephen J, Murphy Michael P, Krieg Thomas
Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Eur J Heart Fail. 2014 Jul;16(7):712-7. doi: 10.1002/ejhf.100. Epub 2014 May 31.
Recently it has been shown that the mitochondria-targeted S-nitrosothiol MitoSNO protects against acute ischaemia/reperfusion (IR) injury by inhibiting the reactivation of mitochondrial complex I in the first minutes of reperfusion of ischaemic tissue, thereby preventing free radical formation that underlies IR injury. However, it remains unclear how this transient inhibition of mitochondrial complex I-mediated free radicals at reperfusion affects the long-term recovery of the heart following IR injury. Here we determined whether the acute protection by MitoSNO at reperfusion prevented the subsequent development of post-myocardial infarction heart failure.
Mice were subjected to 30 min left coronary artery occlusion followed by reperfusion and recovery over 28 days. MitoSNO (100 ng/kg) was applied 5 min before the onset of reperfusion followed by 20 min infusion (1 ng/kg/min). Infarct size and cardiac function were measured by magnetic resonance imaging (MRI) 24 h after infarction. MitoSNO-treated mice exhibited reduced infarct size and preserved function. In addition, MitoSNO at reperfusion improved outcome measures 28 days post-IR, including preserved systolic function (63.7 ±1.8% LVEF vs. 53.7 ± 2.1% in controls, P = 0.01) and tissue fibrosis.
MitoSNO action acutely at reperfusion reduces infarct size and protects from post-myocardial infarction heart failure. Therefore, targeted inhibition of mitochondrial complex I in the first minutes of reperfusion by MitoSNO is a rational therapeutic strategy for preventing subsequent heart failure in patients undergoing IR injury.
最近有研究表明,线粒体靶向性S-亚硝基硫醇(MitoSNO)通过在缺血组织再灌注的最初几分钟内抑制线粒体复合物I的重新激活,从而预防自由基形成,进而保护机体免受急性缺血/再灌注(IR)损伤,而IR损伤正是由自由基形成所导致的。然而,目前尚不清楚再灌注时线粒体复合物I介导的自由基的这种短暂抑制如何影响IR损伤后心脏的长期恢复。在此,我们确定再灌注时MitoSNO的急性保护作用是否能预防心肌梗死后心力衰竭的后续发展。
对小鼠进行30分钟的左冠状动脉闭塞,随后再灌注并恢复28天。在再灌注开始前5分钟给予MitoSNO(100纳克/千克),随后以20分钟的输注速度(1纳克/千克/分钟)给药。在梗死24小时后通过磁共振成像(MRI)测量梗死面积和心脏功能。接受MitoSNO治疗的小鼠梗死面积减小,心脏功能得以保留。此外,再灌注时使用MitoSNO改善了IR后28天的各项结果指标,包括保留收缩功能(左心室射血分数为63.7±1.8%,而对照组为53.7±2.1%,P=0.01)以及组织纤维化情况。
再灌注时MitoSNO的急性作用可减小梗死面积,并预防心肌梗死后心力衰竭。因此,在再灌注的最初几分钟内通过MitoSNO靶向抑制线粒体复合物I是预防接受IR损伤患者后续心力衰竭的合理治疗策略。